F-Star Therapeutics, Inc.
(NASDAQ CM: FSTX)
Rigrodsky Law, P.A. is investigating F-Star Therapeutics, Inc. (“F-Star”) regarding possible breaches of fiduciary duties and other violations of law related to F-Star’s agreement to be acquired by invoX Pharma, a wholly owned subsidiary of Sino Biopharmaceutical Limited. Under the terms of the agreement, F-Star’s shareholders will receive $7.12 in cash for each share of F-Star common stock they own.